Barr's bid for biogenerics line seen as risky by some

09/16/2006 | CNNMoney

Stock analysts are labeling as "risky" the $2.5 billion bid Barr Pharmaceuticals has made for the Croatian Pliva to get access to its biogenerics drug line. Some called the bid by the U.S. generics maker "speculative" for an industry still in early stages of development. Competing bidder Actavis, of Iceland, has until Sept. 27 to top Barr's bid.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA